The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial
Abstract
OBJECTIVE: Depression is the leading cause of disability worldwide, and half of patients with depression have treatment-resistant depression. Intermittent theta-burst stimulation (iTBS) is approved by the U.S. Food and Drug Administration for the treatment of treatment-resistant depression but is limited by suboptimal efficacy and a 6-week duration. The authors addressed these limitations by developing a neuroscience-informed accelerated iTBS protocol, Stanford neuromodulation therapy (SNT; previously referred to as Stanford accelerated intelligent neuromodulation therapy, or SAINT). This protocol was associated with a remission rate of ∼90% after 5 days of open-label treatment. Here, the authors report the results of a sham-controlled double-blind trial of SNT for treatment-resistant depression. METHODS: Participants with treatment-resistant depression currently experiencing moderate to severe depressive episodes were randomly assigned to receive active or sham SNT. Resting-state functional MRI was used to individually target the region of the left dorsolateral prefrontal cortex most functionally anticorrelated with the subgenual anterior cingulate cortex. The primary outcome was score on the Montgomery-Åsberg Depression Rating Scale (MADRS) 4 weeks after treatment. RESULTS: At the planned interim analysis, 32 participants with treatment-resistant depression had been enrolled, and 29 participants who continued to meet inclusion criteria received either active (N=14) or sham (N=15) SNT. The mean percent reduction from baseline in MADRS score 4 weeks after treatment was 52.5% in the active treatment group and 11.1% in the sham treatment group. CONCLUSIONS: SNT, a high-dose iTBS protocol with functional-connectivity-guided targeting, was more effective than sham stimulation for treatment-resistant depression. Further trials are needed to determine SNT's durability and to compare it with other treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The significant ben efit observed was evident despite an average of five prior antidepressant medication trials 249 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [249]
In the citing paper
“An accel erated high- dose iTBS protocol with magnetic resonance imaging (MRI)- guided func tional connectivity targeting (Stanford neuro modulation therapy, SNT) has been found, in a double- blind randomized controlled tri al (RCT), to be significantly superior relative to sham treatment four weeks after the end of the five- day protocol.”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [249]
In the citing paper
“Notably, the SAINT/SNT paradigm, shows rapid and significant effects with remission rates up to 78.6% in randomized controlled trials [108,109,110,111].”
In the citing paper
“In migraines, especially with aura, single-pulse TMS studies report significant reductions in monthly headache days, sustained up to 12 months in difficult-to-treat cohorts [107,108,109,110,111,119,120,121,122], while results for chronic migraine remain inconclusive [117,122].”
In the citing paper
“This general approach was previously reported in a clinical trial using the Stanford Accelerated Intelligent Neuromodulation Therapy for the treatment of depression 53 and subsequently validated in a follow-up study 54 .”
From Stanford Hypnosis Integrated with Functional Connectivity-targeted Transcranial Stimulation (SHIFT): a preregistered randomized controlled trial (2024) · cites this paper as [54]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Assessment of suicidal intention: The Scale for Suicide Ideation.
Beck, A. T., Kovacs, M., & Weissman, A. (1979) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.47.2.343 · Cited by 3,419
O’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.018 · Cited by 1,910
Benedict, R. H. B., Schretlen, D., Groninger, L., & Brandt, J. (1998) · The Clinical Neuropsychologist · doi:10.1076/clin.12.1.43.1726 · Cited by 1,597
Blumberger, D. M., Vila-Rodriguez, F., Thorpe, K. E., Feffer, K., Noda, Y., Giacobbe, P., Knyahnytska, Y., Kennedy, S. H., Lam, R. W., Daskalakis, Z. J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30295-2 · Cited by 1,363
Okamoto, M., Dan, H., Sakamoto, K., Takeo, K., Shimizu, K., Kohno, S., Oda, I., Isobe, S., Suzuki, T., Kohyama, K., et al. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2003.08.026 · Cited by 1,320
Fox, M. D., Buckner, R. L., White, M. P., Greicius, M. D., & Pascual-Leone, A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.04.028 · Cited by 1,270
George, M. S., Lisanby, S. H., Avery, D., McDonald, W. M., Durkalski, V., Pavlicova, M., Anderson, B., Nahas, Z., Bulow, P., Zarkowski, P., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.46 · Cited by 1,092
Research works printed but not linked: 3
- Friedrich MJ, 2017, JAMA, 317, 1517
- Cash RFH, Biol Psychiatry
- Modak A, World J Biol Psychiatry
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationMarx, W., Penninx, B. W. J. H., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00454-1 · Cited by 768
“…is the Stanford Neuromodula-tion Therapy protocol, which requires a reduced duration to prior TMS methods and has demonstrated a 52.5% reduction in reported average depressive symptoms from baseline in the active treatment group compared with 11.1% of participants receiving a sham treatment 220 .”
InfluentialPsilocybin desynchronizes the human brain
Siegel, J. S., Subramanian, S., Perry, D., Kay, B. P., Gordon, E. M., Laumann, T. O., Reneau, T. R., Metcalf, N. V., Chacko, R. V., Gratton, C., et al. (2024) · Nature · doi:10.1038/s41586-024-07624-5 · Cited by 269
“Consistent with this notion, psilocybin produced the largest changes in the DMN, frequently associated with neuropsychiatric disorders 34,35,87–91 , and in a region of the anterior and middle hippocampus associated with the self 29,92 and the present moment 93 .”
Caulfield, K. A., Fleischmann, H. H., Cox, C. E., Wolf, J. P., George, M. S., & McTeague, L. M. (2022) · Brain Stimulation · doi:10.1016/j.brs.2022.08.013 · Cited by 145
Blumberger, D. M., Mulsant, B. H., Thorpe, K. E., McClintock, S. M., Konstantinou, G. N., Lee, H. H., Nestor, S. M., Noda, Y., Rajji, T. K., Trevizol, A. P., et al. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2862 · Cited by 142
Metadata
- Authors
- Cole, E. J., Phillips, A. L., Bentzley, B. S., Stimpson, K. H., Nejad, R., Barmak, F., Veerapal, C., Khan, N., Cherian, K., Felber, E., Brown, R., Choi, E., King, S., Pankow, H., Bishop, J. H., Azeez, A., Coetzee, J., Rapier, R., Odenwald, N., Carreon, D., Hawkins, J., Chang, M., Keller, J., Raj, K., DeBattista, C., Jo, B., Espil, F. M., Schatzberg, A. F., Sudheimer, K. D., & Williams, N. R.
- Affiliations
- Southern Illinois University Carbondale (US)
- Department of Psychiatry and Behavioral Sciences, Stanford University, Palo Alto, Calif. (all authors except King and Sudheimer); U.S. Department of Veterans Affairs, Palo Alto, Calif. (Phillips, Azeez, Coetzee); Department of Psychology, Palo Alto University, Palo Alto, Calif. (Stimpson, Cherian, Felber, Brown, Choi); Centre for Neuroimaging and Cognitive Genomics, National University of Ireland, Galway (King); Department of Anatomy, School of Medicine, Southern Illinois University, Carbondale (Sudheimer).
- ORCID
- Cole, Eleanor J.
- Bentzley, Brandon S.
- Stimpson, Katy H.
- Nejad, Romina
- Khan, Naushaba
- Cherian, Kirsten
- Brown, Randi
- Choi, Elizabeth
- Bishop, James H.
- Azeez, Azeezat
- Coetzee, John
- Odenwald, Nicole
- Carreon, David
- Keller, Jennifer
- Raj, Kristin
- DeBattista, Charles
- Jo, Booil
- Espil, Flint M.
- Schatzberg, Alan F.
- Sudheimer, Keith D.
- Williams, Nolan R.
- Venue
- American Journal of Psychiatry
- Published
- 2022-02
- Volume
- 179
- Issue
- 2
- Pages
- 132-141
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3208689015
- Semantic Scholar
- e244e400ad19605c257a4623dc09a7d4fa31baed
- Cited by
- 795
- References
- 55
- Citations by year
- 2026: 172 · 2025: 185 · 2024: 203 · 2023: 166 · 2022: 66
- FWCI
- 44.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- treatment-resistant depression, intermittent theta burst stimulation, dorsolateral prefrontal cortex, subgenual anterior cingulate cortex, sham stimulation, depression remission
- MeSH terms
- Double-Blind Method, Gyrus Cinguli, Humans, Treatment Outcome, Prefrontal Cortex, Transcranial Magnetic Stimulation, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. https://app.cochat.ai/papers/10.1176/appi.ajp.2021.20101429
- The paper
- Cole, E. J., Phillips, A. L., Bentzley, B. S., Stimpson, K. H., Nejad, R., Barmak, F., Veerapal, C., Khan, N., Cherian, K., Felber, E., Brown, R., Choi, E., King, S., Pankow, H., Bishop, J. H., Azeez, A., Coetzee, J., Rapier, R., Odenwald, N., . . . Williams, N. R. (2022). Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.2021.20101429
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.